Latest publications
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
J Clin Oncol. 2018 Dec 1;36(34):3353-3360.
Necchi A, Anichini A, Raggi D, et al.
Impact of Molecular Subtyping and Immune In ltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
Eur Urol. 2020 Jun;77(6):701-710.
Necchi A, Raggi D, Gallina A, et al.
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy?
First survival outcomes from the PURE-01 study. Ann Oncol. 2020 Dec;31(12):1755-1763.
Bandini M, Gibb EA, Gallina A, et al.
Erda tinib in Locally Advanced or Metastatic Urothelial Carcinoma
N Engl J Med. 2019 Jul 25;381(4):338-348.
Loriot Y, Necchi A, Park SH, et al.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
Lancet Oncol 2012;8:810-16.
Necchi A, Mariani, Zaffaroni N, et al.
Proof of activity of anti-EGFR targeted therapy for relapsed squamous-cell carcinoma of the penis
J Clin Oncol 2011;29:2178-84.
Necchi A, Nicolai N, Colecchia C et al.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
N Engl J Med. 2017 Mar 16;376(11):1015-1026.
Bellmunt J, de Wit R, Vaughn DJ, et al.
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatinineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol
2021 Jun;22(6):872-882.
Yu EY, Petrylak DP, O'Donnell PH, et al.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol. 2020 Dec;21(12):1574-1588.
Powles T, van der Heijden MS, Castellano D, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Lancet Oncol. 2017 Mar;18(3):312-322.
Sharma P, Retz M, Siefker-Radtke A, et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet. 2016 May 7;387(10031):1909-20.
Rosenberg JE, Hoffman-Censits J, Powles T, et al.
Atezolizumab as rst-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet. 2017 Jan 7;389(10064):67-76.
Balar AV, Galsky MD, Rosenberg JE, et al.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Lancet. 2017 Nov 18;390(10109):2266-2277.
Petrylak DP, de Wit R, Chi KN, et al.
Contrasting genomic pro les from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer
Cancer. 2021 Aug 11. doi: 10.1002/cncr.33865. Online ahead of print.
Necchi A, Cucchiara V, Grivas P, et al.
Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumabur
Eur Urol. 2021 Aug;80(2):149-159.
Necchi A, de Jong JJ, Raggi D, et al.
